🌀 IBS-C IBS-D Subtype Treatment Simulator

Bowel Habit Subtyping

Stool pattern sorts IBS into three distinct subtypes.

• 3: Rome IV subtypes (IBS-C, IBS-D, IBS-M)
• 1–7: Bristol scale range (hard to watery stool)
• 10–15%: IBS prevalence (of adults worldwide)
• ~30%: Misclassification risk (delays correct therapy)

Bristol Stool Chart

Type 1–2 signals constipation, type 6–7 signals diarrhea.

Rome IV Criteria

Subtype is set by the dominant stool pattern over time.

Why Subtype Matters

One-size therapy often worsens the wrong subtype.

Giving laxatives to IBS-D patients can trigger severe flares.

Constipation-Predominant Treatment

Fiber, osmotic laxatives, and secretagogues accelerate sluggish transit.

• 20–30g: Soluble fiber dose (psyllium daily target)
• PEG: Osmotic laxative (draws water into colon)
• Linaclotide: Secretagogue class (activates GC-C receptor)
• 40–60%: Response rate (achieve adequate relief)

Fiber & Osmotics

Psyllium and PEG shorten transit time gradually.

Secretagogues

Chloride channels pull water into the gut lumen.

Secretagogues also ease visceral pain, not just constipation.

Prokinetics

Motility agents help speed severe, refractory cases.

Diarrhea-Predominant Treatment

Antidiarrheals, bile sequestrants, and rifaximin calm rapid transit.

• OTC: Loperamide (slows peristalsis, cuts urgency)
• Cholestyramine: Bile acid sequestrant (binds excess bile acids)
• 14 days: Rifaximin course (targets bacterial overgrowth)
• 40–50%: Response rate (achieve adequate relief)

Antidiarrheals

Loperamide slows rushed colonic transit and urgency.

Bile Acid Sequestrants

Cholestyramine binds bile acids, easing chronic diarrhea.

About a third of IBS-D cases involve bile acid malabsorption.

Rifaximin

Nonabsorbed antibiotic reduces fermentation driving urgency.

Toward the Healthy Transit Range

Matched treatment pulls transit time back toward normal.

• 20–45h: Healthy transit time (mouth to stool)
• 70–100h: IBS-C baseline (markedly slowed transit)
• 8–20h: IBS-D baseline (markedly rushed transit)
• 2–4 wk: Normalization window (typical treatment response)

Scintigraphy & Markers

Radiopaque markers track segmental colonic transit speed.

Bidirectional Correction

Fiber slows IBS-D; laxatives speed IBS-C.

Mismatched therapy can push transit further from healthy range.

Monitoring Response

Stool diaries track consistency and frequency trends.

Subtype-Matched Symptom Relief

Correctly matched therapy delivers durable symptom control.

• 60–70%: Matched-therapy relief (adequate relief achieved)
• 15–25%: Mismatched-therapy relief (often worsens symptoms)
• Significant: Quality of life gain (with correct subtyping)
• ~50%: Relapse without upkeep (within 6 months)

Personalized Algorithms

Guidelines stratify treatment choice by Rome IV subtype.

Combination Care

Low-FODMAP diet and CBT reinforce pharmacologic therapy.

Subtype-matched care roughly triples meaningful symptom relief.

Long-Term Outlook

Reassessment keeps therapy aligned as symptoms evolve.